# Additional file 2, in the manuscript:

# A quality indicator set for rehabilitation services for people with rheumatic and musculoskeletal diseases demonstrates adequate responsiveness in a pre–post evaluation

Anne-Lene Sand-Svartrud1\*, Gunnhild Berdal1, Maryam Azimi2, Ingvild Bø3, Turid Nygaard Dager1, Siv Grødal Eppeland4, Guro Ohldieck Fredheim5, Anne Sirnes Hagland6, Åse Klokkeide7, Anita Dyb Linge8, Kjetil Tennebø9, Helene Lindtvedt Valaas5, Ann Margret Aasvold10, Hanne Dagfinrud1 and Ingvild Kjeken1

1National Advisory Unit on Rehabilitation in Rheumatology, Diakonhjemmet Hospital, PO Box 23 Vinderen, N- 0319 Oslo, Norway.

2Diakonhjemmet Hospital, PO Box 23 Vinderen, N- 0319 Oslo, Norway.

3Hospital for Rheumatic Diseases Lillehammer, Margrethe Grundtvigs veg 6, N-2609 Lillehammer, Norway.

4Sørlandet Hospital Arendal, PO Box 416 Lundsiden, N-4604 Kristiansand,Norway.

5Vikersund Rehabililation Center, Haaviks vei 25, N-3370 Vikersund, Norway.

6Hosptial for Rheumatic Diseases Haugesund, PO Box 2175, N-5504 Haugesund, Norway.

7Rehabilitering Vest Rehabiliation Center, PO Box 2175, N-5504 Haugesund, Norway.

8Muritunet Rehabiliation Center, Grandedata 58, N-6210 Valldal, Norway.

9Valnesfjord Health Sports Center, Østerkløftveien 249, N-8215 Valnesfjord, Norway.

10Meråker Rehabiliation Center, Østigardsveien 24, N-7530 Meråker, Norway.

\*Corresponding author. Correspondence: anne-lene.svartrud@diakonsyk.no

|  |
| --- |
| **Additional file 2** Baseline characteristics of patients in the BRIDGE-trial when the QI-set was distributed (n=357) |
|  | T1-group (n = 200) | T2-group (n = 157) | p-value |
| Age, years, mean (min, max) | 52 (21,81) | 49 (18,77) | 0.0051 |
| Gender, female, n (%) | 148 (74) | 123(78) | 0.3412 |
| Diagnosis, n (%) Inflammatory rheumatic disease (SpA, PsA, RA, JRA) Osteoarthritis  Connective tissue disease (SLE, SS, PMR, MCTD) Fibromyalgia syndrome, CWP Unspecific neck-, shoulder- and low back pain (>3 months)  | 143 (72) 8 (4) 14 (7) 20 (10) 15 (8) | 85 (54) 5 (3) 6 (4)51 (32)10 (6) | <0.0012 |
| Disease duration, years, median (min, max) |  17 (1,67) | 13 (0,68) | 0.0143 |
| Comorbidities, n, median (min , max) |  2.5 (0,9) |  3 (0,9) | 0.3343 |
| Medication usage NSAIDs, n (%) Disease modifying anti-rheumatic drugs (DMARDs), n (%) TNF-inhibitors, Biosimilars, JAK-inhibitors n (%) Analgesics, n (%) Other drugs, n (%) |  80 (43) 68 (37) 42 (23)131 (70)135 (73) |  76 (53) 51 (36) 26 (18)103 (72)107 (75) | 0.06820.86720.32920.75120.6472 |
| BMI (kg/m2), median (min, max) |  28 (17,66) |  28 (17,50) | 0.6623 |
| Smokers, n (%) |  57 (29) |  37 (24) | 0.3302 |
| Snuff users, n (%) |  19 (10) |  13 (9) | 0.7042 |
| Education > 12 years, n (%) |  80 (40) |  67 (44) | 0.5582 |
| Paid work, n (%) |  85 (43) |  69 (45) | 0.6642 |
| Recipients of social security benefits, n (%) | 139 (81) | 120 (87) | 0.1782 |
| Living with partner, n (%) | 140 (70) | 103 (67) | 0.4852 |
| Physical exercise ≥ 1 per week, n (%) | 123 (62) |  81 (53) | 0.0822 |
| General activity ≥ 1 per week, n (%) | 147 (74) | 104 (68) | 0.2202 |

*1Independent Samples T-test, 2Pearson Chi Square test, 3Mann Whitney U test. SpA: spondyloarthritis, PsA: psoriatic arthritis, RA: rheumatoid arthritis, JRA: juvenile rheumatoid arthritis, SLE: systemic lupus erythematosus, SS: Sjögren syndrome, PMR: polymyalgia rheumatica, MCTD: mixed connective tissue disease, CWP: chronic widespread pain. Disease duration (symptom debut) and comorbidities are self-reported. NSAIDs: nonsteroidal anti-inflammatory drugs, DMARDS include corticosteroids, TNF: tumor necrosis factor, JAK: Janus Kinase. BMI: body mass index (bodyweight/height2). Physical exercise: increased heart rate and breathing for 30 minutes or longer. General activity: social or cultural activities, hobbies, work.*